**COMBINED DYSLIPIDEMIA IN CHILDREN AND ADOLESCENTS**

**Rae-Ellen W. Kavey, MD, MPH**, University of Rochester Medical Center, Rochester, New York. rekavey@gmail.com

**Updated May 9, 2023**

**ABSTRACT**

Combined dyslipidemia (CD) is now the predominant hyperlipidemic pattern in childhood, characterized by moderate to severe elevation in triglycerides (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) with reduced high-density lipoprotein cholesterol (HDL-C). In youth, CD occurs almost exclusively with obesity and is highly prevalent, seen in 30-60% of obese adolescents. With nuclear magnetic resonance spectroscopy, the CD pattern is represented as increased small, dense LDL and overall LDL particle number and decreased total HDL-C and large HDL particles, a highly atherogenic pattern. CD in childhood is associated with pathologic evidence of atherosclerosis and ultrasound findings of vascular dysfunction in children, adolescents, and young adults; it is also predictive of early clinical cardiovascular events in adult life. CD is strongly associated with visceral adiposity, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and the metabolic syndrome, suggesting an underlying, integrated pathophysiologic response to excessive weight gain. In almost all cases, CD responds well to lifestyle intervention including weight loss, changes in dietary composition, and increased physical activity. Evidence-based recommendations for management of CD are provided. Rarely, drug therapy is needed and the evidence for drug treatment of CD in childhood is reviewed.

**DEFINITION, ATHEROGENICITY, AND PREVALENCE**

The pediatric obesity epidemic has resulted in a large population of children and adolescents with secondary combined dyslipidemia (CD). This is now the predominant hyperlipidemic pattern in childhood, characterized by moderate to severe elevation in triglycerides (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) with reduced high-density lipoprotein cholesterol (HDL-C) (1).

Analysis by nuclear magnetic resonance spectroscopy (NMR) shows that the combined dyslipidemia pattern on standard lipid profile is represented at the lipid subpopulation level as increased small, dense LDL and LDL particle number with decreased total HDL-C and large HDL particles (2,3,4). High LDL particle number and elevated small, dense LDL particles have each been shown to predict clinical cardiovascular disease (5-11). The atherogenicity of this lipid sub-population pattern is complex and includes the high concentration of circulating LDL particles, decreased binding of small, dense LDL particles to the LDL receptor, prolonged residence time in plasma and therefore prolonged arterial wall exposure, greater binding of small, dense LDL particles to arterial wall proteoglycans, and increased susceptibility to oxidation (12-18). Consistent with these findings, genetic evidence from mutational analyses, genome-wide association studies, and Mendelian randomization studies indicates that triglycerides and triglyceride-rich lipoproteins are an important source of increased small, dense LDL particle populations. The combined dyslipidemia pattern on traditional lipid profile analysis identifies the atherogenic pattern on lipid sub-population analysis.

Obesity is highly prevalent, affecting 18.5% of all-American youth and 20.6% in adolescents based on NHANES data from 2015-2016; up to 85% of overweight adolescents become obese adults (19,20). In the short term, 50% of obese adolescents have at least one, and 10% have 3 or more cardiovascular risk factors, including combined dyslipidemia, hypertension, and insulin resistance (21,22). In the long term, childhood obesity predicts type 2 diabetes mellitus, premature cardiovascular disease (CVD), and early mortality [(23)](#_ENREF_4). NHANES data from 1999-2006 indicated CD was highly prevalent in obese youth, present in more than 40% of adolescents with body mass index (BMI) >95th%ile (24). A 2019 analysis of trends in fasting serum lipids using NHANES data from 1999-2000 to 2015-2016 in US adolescents aged 12 to 19 years showed significant favorable changes in mean levels of all lipid parameters for the sample population as a whole. By contrast, when analyzed by BMI category, obese adolescents showed no significant trend towards improvement in mean HDL-C or LDL-C levels. Although there was a trend towards improvement among obese subjects in total cholesterol, TGs, and non-HDL-C, the prevalence of adverse levels in the last survey in 2015-2016 remained high: 22.3% for TGs, 29% for HDL-C and 10% for LDL-C (25). In cross-sectional data from multiple populations, 30 to 60% of obese youth have elevated TGs, usually associated with reduced HDL-C (26-28). The prevalence of CD increases as obesity severity increases (29-31).

In addition, selected second generation antipsychotic medications, increasingly prescribed in pediatric patients, are associated with severe weight gain and significant increases in triglycerides and reductions in HDL-C (32,33). Thus, CD is a prevalent and important problem.

**LIPID PROFILE MEASURES**

Normal lipid values in childhood are shown in Table 1 (1). In children younger than 10 years, the 95th%ile for TG is 100 mg/dL and at 10-18 years, the 95th%ile is 130 mg/dL. Normal non-HDL-C levels are <145 mg/dL. HDL-C averages 55 mg/dL in males and females before puberty, after which mean HDL-C drops to a mean of 45 mg/dL in males. The diagnosis of CD requires that the average of a least 2 measurements of TG and/or non-HDL-C fall above the 95th%ile, plus HDL-C at or below the 5th%ile. TC and LDL-C levels may also be mildly elevated. In the typical lipid profile of a child or adolescent with CD, TG levels are between 150 and 400 mg/dL, HDL-C is < 40mg/dL, non-HDL-C is >145 mg/dL and TG/HDL-C ratio exceeds 3 in whites and 2.5 in blacks.

|  |
| --- |
| **Table 1. Acceptable, Borderline, and High Plasma Lipid and Lipoprotein Concentrations (mg/dL) for Children and Adolescents\*** (1) |
| **Category** | **Acceptable** | **Borderline**  | **High** |
| **TC** | < 170 | 170-199 | > 200 |
| **LDL-C** | < 110 | 110-129 | > 130 |
| **Non-HDL-C**  | < 120 | 120-144 | > 145 |
| **Triglycerides** |
| 0-9 years | < 75 | 75-99 | > 100 |
| 10-19 years | < 90 | 90-129 | > 130 |
| **Category**  | **Acceptable**  | **Borderline**  | **Low** |
| **HDL-C** | >45 | 40-45 | <40 |

NOTE: Values given are in mg/dL; to convert to SI units, divide the results for TC, LDL-C, HDL-C and non-HDL-C by 38.6; for TG, divide by 88.6.

**\*** Values for plasma lipid and lipoprotein levels are from the 2011 NHLBI Expert Panel Guidelines (1). The cut points for high and borderline high represent the 95th and 75th percentiles, respectively. The low-cut point for HDL-C represents the 10th percentile.

[www.nhlbi.nih.gov/guidelines/cvd\_ped/index.htm](http://www.nhlbi.nih.gov/guidelines/cvd_ped/index.htm).

In addition to the standard lipid profile measures, non-HDL-C and the TG/HDL-C ratio are useful measures in patients being evaluated for CD. Non-HDL-C is a measure of the cholesterol content of all the plasma atherogenic lipoproteins. TC and HDL-C can be measured accurately in the non-fasting state with non-HDL-C calculated by subtracting HDL-C from TC (1). Epidemiologic studies show that childhood non-HDL-C correlates well with adult levels, independent of baseline BMI and BMI change (34). In autopsy studies in children, adolescents and young adults, non-HDL-C and HDL-C levels were the best lipid predictors of pathologic atherosclerotic lesions, better than any other lipid measure (35). Non-HDL-C measured in childhood was a significant predictor of subclinical atherosclerosis in adulthood, assessed by higher carotid intima media thickness (cIMT) measurements (36). In adults, non-HDL-C has been shown to be the best independent lipid predictor of cardiovascular disease events (37,38). Normative values for non-HDL-C are included in the 2011 NHLBI pediatric guidelines which recommend this measure for population screening (1) (Table 1).

The TG/HDL-C ratio is a strong predictor of coronary disease extent in adults and is considered to be a surrogate index of the atherogenicity of the plasma lipid profile (39,40). In children, an elevated TG/HDL-C ratio correlates with insulin resistance and with non-alcoholic fatty liver disease (41-43). In a study of normal weight, overweight, and obese white children and adolescents, top tertile TG/HDL-C correlated significantly with increased cIMT in multivariate analysis (43). There are ethnic differences in lipid measures which manifest during adolescence: African-Americans have significantly lower triglycerides and higher HDL-C levels and this impacts non-HDL-C and the TG/HDL-C ratio (44-47). In a study of obese black and white adolescents, TG/HDL-C and non-HDL-C were surrogate markers for elevated small dense lipoprotein particles on NMR spectroscopic analysis (48). A TG/HDL-C ratio above 3 and non-HDL-C above 120 mg/dL in white subjects, and TG/HDL-C ratio above 2.5 and non-HDL-C levels above 145 mg/dL in black subjects were the best lipid predictors of LDL-C particle concentration (48). The HEALTHY study characterized lipids in a large, diverse population of sixth grade children and found that 33% of overweight/obese children had an elevated TG/HDL-C ratio and 11.2% had an elevated non-HDL-C (49). NMR spectroscopy confirmed that the CD findings on standard lipid profile identified the lipid subpopulation pattern of increased total and small, dense LDL particles (50).

**GENETIC ASPECTS OF COMBINED DYSLIPIDEMIA**

In the literature, the terminology describing combined dyslipidemia also includes “mixed dyslipidemia” and “atherogenic dyslipidemia” (51,52). Combined dyslipidemia is the term used most commonly in pediatrics (53). There is overlap in the lipid phenotype between CD and familial combined hyperlipidemia (FCHL), which was originally considered to be a genetically discrete entity (54,55). However, current evidence suggests that FCHL is a multigenic dyslipidemia with variable expression in different pedigrees (56,57). There is well-established familial aggregation of the combined dyslipidemia phenotype in pediatric and adult studies, beyond the historic studies of FCHL (58,59). Emerging evidence from gene sequencing studies suggests that variants in the genes controlling TG metabolism, particularly those encoding lipoprotein lipase, may be important factors in the expression of hypertriglyceridemia and combined dyslipidemia (59,60). As with CD, the mechanism of increased CVD risk in FCHL is the presence of increased numbers of apolipoprotein B-containing particles, particularly small, dense LDL particles, so genetic analysis is not critical for patient management at this time (61,62).

**EVIDENCE FOR ACCELERATED ATHEROSCLEROSIS WITH COMBINED DYSLIPIDEMIA**

An important initiating step in atherosclerosis is subendothelial retention of LDL-containing lipoproteins (63). Combined dyslipidemia is highly atherogenic because its sub-population composition with increased LDL particles and small dense LDL is associated with facilitated sub-endothelial retention by multiple mechanisms (12-18). Consistent with these findings, recent genetic evidence from mutational analyses, genome-wide association studies, and Mendelian randomization studies indicates that triglycerides and triglyceride-rich lipoproteins are an important source of increased small, dense LDL particle populations. In childhood, the atherogenicity of combined dyslipidemia is seen in anatomic and histologic changes at autopsy and with structural and functional vascular changes in vivo. CD in childhood is also predictive of accelerated atherosclerosis and of early cardiovascular events in adult life. In both the Pathobiological Determinants of Atherosclerosis in Youth Study and the Bogalusa Heart Study, high non-HDL-C and low HDL-C were strongly associated with autopsy evidence of premature atherosclerosis (64-66). Obese youth with elevations in TG and low HDL-C had thicker CIMT, higher pulse wave velocity (PWV), and increased carotid artery stiffness (67-69). A strong association between higher TG/HDL-C ratio, higher non-HDL-C, and higher PWV in both lean and obese children has been demonstrated after adjustment for other CVD risk factors (70). CD identified in childhood is associated with atherosclerotic vascular change measured in adulthood by CIMT and PWV (71-73). Most importantly, in the long-term Princeton Follow-up Study, elevated TG and TG/HDL-C ratio at a mean age of 12 years predicted clinical cardiovascular events at late follow-up 3 to 4 decades later (74,75). This is the first childhood lipid parameter shown to be associated with premature clinical cardiovascular disease. Thus, the combined dyslipidemia pattern seen with obesity in childhood and adolescence identifies pathologic evidence of atherosclerosis and vascular dysfunction in adolescence and young adulthood, and predicts early clinical events in adult life.

While evidence like this in pediatrics strongly supported the importance of high triglycerides/ combined dyslipidemia in the development of atherosclerotic vascular change and subsequent premature cardiovascular clinical cardiovascular disease, LDL-C has been the principal, long-time focus for investigation and management in adult atherosclerosis. Since the time this chapter was first developed in 2016, a flurry of studies in adults have addressed the importance of hypertriglyceridemia – the “neglected major cardiovascular risk factor” – in atherogenesis (76). These include epidemiologic studies which identify high serum TGs as a marker for TG-rich lipoproteins, now recognized as strong, independent predictors of ASCVD and all-cause mortality; Mendelian randomization studies which identify TG-rich lipoproteins as causally associated with ASCVD and all-cause mortality; and intervention trials identifying high TGs and non-HDL-C as the mediators of residual atherosclerotic risk when LDL-C levels are below prescribed targets (77-80). Unfortunately, as discussed in other Endotext chapters, recent randomized trials using triglyceride lowering drugs have failed to demonstrate a decrease in atherosclerotic cardiovascular events in adults.

**PATHOPHYSIOLOGIC ASSOCIATIONS**

There is a tight connection between CD and obesity, visceral adiposity, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and the metabolic syndrome.

**Obesity**

The association between CD and obesity is strong and consistent with CD seen in 20 to 60% of obese youth (25-27). The prevalence of CD increases as obesity severity increases (28-30). In multiple studies, excessive intake of sugars, particularly fructose, has been associated with obesity and with combined dyslipidemia in children and adults (81-87). By contrast, low sugar intake is associated with higher HDL in females during adolescence (88).

**Visceral Adiposity**

There is a close correlation between CD and abdominal obesity. In susceptible individuals with an underlying racial/ethnic/familial/genetic predisposition*,* excessive weight gain occurs disproportionately as visceral fat (VAT). This is thought to reflect the inability of the subcutaneous adipose tissue depot to expand, resulting in ectopic fat deposition, primarily in the viscera but also in the liver, heart, and skeletal muscle (89,90). Based on correlation with dual-energy x-ray absorptiometry, waist circumference (WC) is an effective measure of abdominal obesity in youth, with WC above the 90th %ile for age and sex strongly predicting high TGs, reduced HDL-C, and hyperinsulinemia (91,92). Using NHANES norms for WC, the prevalence of abdominal obesity increased more than 65% in boys and girls aged 2 to 19 years between 1988-1994 and 1999-2004 (93,94). From NHANES survey results in 5- to 18-year-olds from 1999 to 2008, waist/height ratio (WHtR), another measure of central adiposity, was integrated with BMI percentiles and measures of cardiometabolic risk: obese subjects with normal WHtR < 0.5 had cardiometabolic risk similar to subjects with normal BMI percentiles, while increasing WHtR was significantly associated with dyslipidemia, insulin resistance and the metabolic syndrome (95).

There are known racial/ethnic differences in the tendency to develop visceral adiposity with Hispanic, Native-American, and Asian populations at elevated risk (96). Especially in Asians, increased VAT can develop in the absence of any other measure of adiposity and this is associated with hypertriglyceridemia, CD, insulin resistance, and type 2 diabetes (T2DM) (97), VAT contributes directly to high TGs because delivery of FFAs to the liver via the portal vein is proportionate to visceral fat mass. Progression of VAT correlates significantly with development of CD (98)

**Insulin Resistance and Type 2 Diabetes**

Insulin resistance is considered a primary abnormality in development of CD and associated cardiovascular disease. Obesity correlates with hyperinsulinemia in children, adolescents, and adults (99,100). In the Bogalusa Heart Study, serial cross-sectional surveys showed that higher BMI was associated with higher fasting insulin levels in childhood and adolescence and with higher fasting glucose levels in young adulthood (101). Insulin resistance (IR) correlates strongly with abdominal obesity, high TGs, and reduced HDL-C in children, adolescents, and adults. During puberty, insulin resistance is physiologic with an average 50% decrease in insulin sensitivity, associated with compensatory doubling of insulin secretion to maintain glucose homeostasis. The pattern of insulin resistance is exaggerated in obese adolescents and persists after puberty is complete (102).

Hyperinsulinemia enhances hepatic VLDL synthesis, manifest as high TGs (103). At the tissue level, IR promotes lipoprotein lipase dysfunction, further elevating TGs (104). In normoglycemic adolescents, IR and CD were seen only in obese subjects and the dyslipidemia correlated with the degree of IR (105). In a hyperinsulinemic–euglycemic clamp study, elevated TGs with reduced HDL-C identified *in vivo* IR (41).

Progression from IR to impaired fasting glucose to type 2 diabetes (T2DM) has been documented in youth, especially with a family history of diabetes (101). T2DM is increasingly common in adolescents with a prevalence of 0.46 per 1000 individuals in 2009, a 31% increase from 2001 (106). In children and adults, the interplay between insulin resistance and dyslipidemia in normoglycemic and hyperglycemic individuals is complex and at this time, incompletely elucidated (107).

**Non-Alcoholic Fatty Liver Disease**

CD is also strongly linked with non-alcoholic fatty liver disease (NAFLD), defined as hepatic fat infiltration in >5% of hepatocytes with no evidence of hepatocellular injury on liver biopsy and no history of alcohol intake (109). NAFLD is highly correlated with obesity, affecting at least 38% of obese adolescents in autopsy series and ~50% in epidemiologic surveys (109,110). On evaluation, the most common findings are hepatomegaly and mild-to-moderate elevation in serum alanine aminotransferase (ALT) (108). Hepatic fat deposition usually occurs in the context of generalized obesity but reflects much more strongly, the presence of increased visceral adiposity. In obese children and adolescents, sequential increase in waist circumference, a proxy measure of visceral fat, is associated with progressive increase in odds ratio for prediction of ultrasound-detected hepatic steatosis (112). NAFLD is strongly associated with insulin resistance and all of the components of the metabolic syndrome (112-114). In a study of adolescents with biopsy-proven NAFLD, 80% had biochemical evidence of insulin resistance (114). In more than half of subjects with NAFLD, the atherogenic CD pattern is seen on a standard lipid profile and with NMR analysis (115). As with CD, dietary sugar is considered to play a significant role in the development and progression of NAFLD – in a recent randomized controlled trial, provision of a diet low in free sugar content for 8 weeks led to significant improvements in hepatic steatosis (116). In children and adolescents, NAFLD is associated with atherosclerosis at autopsy and with ultrasound vascular markers associated with atherosclerosis (117). In adults, NAFLD has been shown to be a strong, independent predictor of CVD (118).

**Metabolic Syndrome**

CD, insulin resistance, and visceral adiposity are each components of the metabolic syndrome (MS), first described by Reaven in 1988 and identified as a high-risk constellation for atherosclerotic disease (119). Non-alcoholic fatty liver disease (NAFLD) has been added as a sixth component of the metabolic syndrome (120). In the U.S., the metabolic syndrome is reported in 23% of adults, including 7% of men and 6% of women in the 20- to 30-year-old age group (121,122). There is as yet no agreed-upon definition for the metabolic syndrome in childhood, but analysis of cross-sectional data from NHANES (1988-1994) revealed the MS cluster in 28.7% of obese adolescents compared with 0.1% of those with a BMI below the 85th percentile. As age and the degree of obesity increased, the prevalence of the MS cluster increased, reported in 38.7% of moderately obese (mean body mass index [BMI] 33.4 kg/m2) and 49.7% of severely obese (mean BMI 40.6 kg/m2) adolescents (123,124). Presence of the metabolic syndrome cluster at a mean of 12 years of age was an independent predictor of adult cardiovascular disease 25 years later (125).

**Summary**

CD is strongly associated with a complex of related cardiometabolic factors. From existing studies, it appears that visceral adiposity develops in children and adolescents with underlying racial/ethnic/familial/genetic susceptibility in response to excessive weight gain. This initiates a cascade of pathophysiologic reactions which result in CD, insulin resistance/ T2DM, and NAFLD and combined, the metabolic syndrome. These prevalent combinations are powerful predictors of cardiometabolic risk (1,115,116).

**MAKING THE DIAGNOSIS OF COMBINED DYSLIPIDEMIA**

The 2011 NHLBI pediatric guidelines were the first to recognize the importance of high TGs and CD in childhood (1). The guidelines recommend selective lipid screening when overweight or obesity is first identified (BMI > 85th%ile for age/sex); when any other major cardiovascular risk is present; and when there is a family history of early cardiovascular disease or of treated dyslipidemia (1). While non-fasting measures of total cholesterol and HDL–C are accurate and non-HDL-C can be used for general screening, hypertriglyceridemia can only be identified on a fasting lipid profile (FLP) so a FLP is recommended for selective screening in these settings.

* Normative values for the lipid components are shown in table 1 with values above the 95th%ile considered elevated for TC, TG, non-HDL-C, and LDL-C; and below the 5th%ile considered as reduced for HDL-C.
* If the first FLP results are abnormal, testing should be repeated after 2 weeks but before 3 months and results averaged to determine baseline lipid values.
* Measurement of TGs is subject to considerable biologic variability with median variation between measurements of 23.5% compared with ~ 5-6% for cholesterol and HDL-C so if the first 2 test results are highly disparate, a third fasting measurement is recommended (127,128).
* For the rare child with CD in whom TGs consistently exceed 500 mg/dL and who is at risk for pancreatitis, treatment is described in detail in the NHLBI guidelines and in other Endotext chapters (1).
* When high TGs or CD are confirmed, specific evaluation for co-morbidities is recommended:
* Waist circumference and WHtR as measures of visceral adiposity (91-93)
* Assessment of fasting glucose to evaluate glucose intolerance per the recommendations of the American Diabetic Association (129)
* ALT measurement to check for NAFLD (108)
* Evaluation for the MS cluster

As noted, there are racial, ethnic and gender differences in TG levels in childhood and adolescence. African-Americans have significantly lower triglycerides and higher HDL-C levels compared with Hispanics and non-Hispanic whites (45-47). With puberty, HDL-C levels drop a mean of 10 mg/dL in males with no change in females, regardless of race/ethnicity (1). These differences suggest that race-, gender- and developmental stage-specific cut points may be needed to optimally identify high TGs and CD but normative tables for American youth based on these factors are not currently available.

**LIFESTYLE MANAGEMENT OF COMBINED DYSLIPIDEMIA**

**Evidence for Response to Lifestyle Changes**

Multiple studies have shown significant improvements in CD in response to weight loss, change in diet composition, and increased activity (130). In all age groups, even small amounts of weight loss are associated with significant decreases in TGs, often with increases in HDL–C (1,131-137). In adults, weight loss of as little as 5% results in a 20% decrease in TGs and an 8 to 10 % increase in HDL-C (133). In youth, a decrease in BMI z-score of at least 0.15 kg/m2 is associated with significant improvement in triglycerides and HDL-C (134). The magnitude of TG decreases correlates directly with the amount of weight loss. Acute weight loss in children and adolescents has been shown to significantly decrease TGs and LDL particles and small dense LDL on NMR analysis (137).

Changes in diet composition have also been shown to be an effective treatment for high TGs and CD. In light of the strong evidence in children and adults associating excessive sugar intake with obesity and with combined dyslipidemia, decreasing simple carbohydrate intake especially in the form of added sugars is a common and important focus (73-80). In adults, a low-carbohydrate diet with monounsaturated fat enrichment significantly decreased TGs by a mean of 63%, with associated increases in HDL–C (138). One-year follow-up of young children (mean age 21 months) with elevated TGs treated with a diet restricted in sugar and carbohydrates was associated with a significant TG decrease from a mean of 274.1 +/- 13.1 mg/dL before treatment to 88.8 +/- 13.3 mg/dL (139). In adolescents and young adults, low glycemic-load diets are as effective as low-fat diets in achieving weight loss and are associated with decreased TGs and increased HDL-C (140-143). In obese children and adolescents, a low-carbohydrate diet with or without weight loss significantly reduces TGs (144,145). These diet composition changes have also been shown to significantly improve the LDL subpopulation pattern (138,148). Combined, diet composition changes lower TGs by at least 20% (135).

Exercise has also been effective in treating CD in youth, alone and in the context of a weight loss plan. Aerobic activity facilitates the hydrolysis and utilization of triglycerides in skeletal muscle, reducing deposition as adipose tissue. In adults, moderately intense activity vs no activity was associated with 20% lower TGs, with lowest levels in the highest activity subjects (147). In cross-sectional studies in youth, low cardiorespiratory fitness is a strong predictor of high triglycerides as part of the MS cluster, and high fitness is associated with a low metabolic risk score (149-151). In randomized controlled trials, aerobic exercise interventions are associated with significant decreases in TG levels and increases in HDL-C, proportionate to training intensity (152-155).

Several studies have attempted to define the optimal type, volume, and intensity of activity required for cardiovascular risk reduction. A systematic review of activity-related benefits concluded that youth aged 5 to 17 years required at least 60 minutes of at least moderate intensity activity every day (156). Aerobic activities should make up the majority, at vigorous intensity whenever possible. These recommendations are very similar to the Physical Activity Guidelines from the U.S. Department of Health and Human Services (157). A randomized, controlled trial in obese children showed that 20 or 40 minutes of supervised aerobic exercise 5 days per week demonstrated dose-response benefits for insulin resistance and visceral adiposity, both strongly associated with CD (158). Pooled data from the International Children’s Accelerometry Database shows that replacement of 10 mins of sedentary time/day with 10 minutes of moderate-to-vigorous activity was associated with significantly lower fasting insulin and TG levels (159).

No studies of youth with high TGs or CD have evaluated clinical cardiovascular events in response to lifestyle changes initiated in childhood. However, in longitudinal cohort studies, low cardiovascular risk in childhood is significantly predictive of better vascular health in adulthood and lifestyle interventions have been shown to improve vascular measures (160-162). In obese youth with high TGs and CD, diet and exercise intervention studies show that subjects who were successful in weight loss showed improvements in vascular measures (163-165).

**Lifestyle Intervention: Diet and Exercise Recommendations**

With this evidence, primary recommended treatment for CD and for related visceral adiposity, IR, and NAFLD is weight loss with optimized diet composition. A comprehensive**,** straightforward weight management approach can be initiated in any practice setting, beginning with calculation of appropriate energy intake for age, gender, and activity using table 2 from the 2011 NHLBI pediatric guidelines (1). Estimation of current caloric intake allows development of a plan to gradually decrease calories towards the appropriate level over several weeks with the guidance of a registered dietitian.

|  |
| --- |
| **Table 2. Estimated Calorie Requirements (in Kilocalories [kcals]) for Gender and Age Group at Three Levels of Physical Activitya**  |
|  | **Calorie Requirements (kcals) by Activity Level** [**b**](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#footb3#footb3)**,**[**c**](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#footc3#footc3)**,**[**d**](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#footd3#footd3) |
| **Gender** | **Age (Years)** | **Sedentary**[**b**](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#footb3#footb3) | **Moderately Active**[**c**](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#footc3#footc3) | **Active**[**d**](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#footd3#footd3) |
| Child | 2–3 | 1,000 | 1,000–1,400[e](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#foote3#foote3) | 1,000–1,400[e](http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm#foote3#foote3) |
| Female | 4–89–1314–1819–30 | 1,2001,6001,8002,000 | 1,400–1,6001,600–2,0002,0002,000–2,200  | 1,400–1,8001,800–2,2002,4002,400 |
| Male | 4–89–1314–1819–30 | 1,4001,8002,2002,400 | 1,400–1,6001,800–2,2002,400–2,8002,600–2,800 | 1,600–2,0002,000–2,6002,800–3,2003,000 |

(Estimates determined using the Institute of Medicine equation & rounded to nearest 200 kcals.)

**a** These levels are based on Estimated Energy Requirements from the IOM *Dietary Reference Intakes* macronutrients report (2002), calculated by gender, age, and activity level for reference-size individuals. “Reference size,” as determined by the IOM, is based on median height and weight for ages up to age 18 years and median height and weight for that height to give a body mass index of 21.5 for adult females and 22.5 for adult males.

b A sedentary activity level in childhood, as in adults, means a lifestyle that includes only the light physical activity associated with typical day-to-day life.

c Moderately active in childhood means a lifestyle that includes some physical activity, equivalent to an adult walking about 1.5 to 3 miles per day at 3 to 4 miles per hour, in addition to the light physical activity associated with typical day-to-day life.

d Active means a lifestyle that includes more physical activity, equivalent to an adult walking more than 3 miles per day at 3 to 4 miles per hour, in addition to the light physical activity associated with typical day-to-day life.

Diet composition is focused on limitation of simple carbohydrates especially sweets and added sugars with complete elimination of all sugar-sweetened beverages. The diet recommendations from the NHLBI guidelines are shown in table 3.

|  |
| --- |
| **Table 3. DIET COMPOSITION: Healthy Lifestyle/ Combined Dyslipidemia/ High TGs**  |
| * 1) Teach portions based on estimated energy requirements for age/gender/activity level. (Table 2**)**
 |
| * 2) Primary beverage: Fat-free unflavored milk.
 |
| * 3) No sugar-sweetened beverages; encourage water intake.
 |
| * 4) Limit refined carbohydrates (sugars, baked goods, white rice, white bread, plain pasta), replacing with complex carbohydrates (brown rice, whole grain bread, whole grain pasta).
 |
| * 5) Encourage dietary fish content\*
* \* The Food and Drug Administration (FDA) and the Environmental Protection Agency are advising women of childbearing age who may become pregnant, pregnant women, nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are lower in mercury. For more information, call the FDA’s food information line toll free at 1–888–SAFEFOOD or visit: <http://www.cfsan.fda.gov/~dms/admehg3.html>
 |
| * 6) Fat content:
	+ Total fat 25–30% of daily kcal/EER Saturated fat </= 8% of daily kcal/EER

Cholesterol <300 mg/d Avoid *trans* fats as much as possible Mono- and polyunsaturated fat up to 20% of daily kcal/ EER  |
| * 7) Encourage high dietary fiber intake from naturally fiber-rich foods (fruits, vegetables, whole grains) with a goal of “age plus 5 g/d.
 |

These diet recommendations are those recommended for all healthy children over age 2 from the NHLBI Guidelines with intensification of limitation of simple carbohydrates.

Simple carbohydrates like white rice, white bread, and plain pasta are replaced with complex carbohydrates like brown rice and whole grain bread and pasta. Foods high in natural fiber are encouraged with a goal of age plus 5 grams per day. For all dietary change in youth, initial family-based training with a registered dietitian is the most effective way to begin and sustain change (1). The DASH eating plan adapted for children and adolescents as part of the 2011 NHLBI guidelines reflects the recommended TG/CD diet composition and is easy to use, organized for selected energy(kcal) intake from table 2 and by servings per day per food group (Table 4) (1).

|  |
| --- |
| **Table 4. DASH-Style Eating Plan: Servings per Day by Food Group & Total Energy Intake.**  |
| **Food Group** | **1,200 Calories** | **1,400 Calories** | **1,600 Calories** | **1,800 Calories** | **2,000 Calories** | **2,600 Calories** | **Serving Sizes** | **Examples and Notes** | **Significance of Food Group to DASH Eating Plan** |
| Grains\* | 4-5 | 5-6 | 6 | 6 | 6–8 | 10-11 | 1 slice bread1 oz dry cereal**⁯**½ cup cooked rice, pasta, or cereal† | Whole- wheat bread and rolls, whole-wheat pasta, English muffin, pita bread, bagel, cereals, grits, oatmeal, brown rice, unsalted pretzels and popcorn | Major sources of energy and fiber |
| Vegetables | 3-4 | 3-4 | 3-4 | 4-5 | 4–5 | 5-6 | 1 cup raw leafy vegetable½ cup cut-up raw or cooked vegetable½ cup vegetable juice | Broccoli, carrots, collards, green beans, green peas, kale, lima beans, potatoes, spinach, squash, sweet potatoes, tomatoes | Rich sources of potassium, magnesium, and fiber |
| Fruits | 3-4 | 4 | 4 | 4-5 | 4–5 | 5-6 | 1 medium fruit¼ cup dried fruit½ cup fresh, frozen, or canned fruit½ cup fruit juice | Apples, apricots, bananas, dates, grapes, oranges, grapefruit, grapefruit juice, mangoes, melons, peaches, pineapples, raisins, strawberries, tangerines | Important sources of potassium, magnesium, and fiber |
| Fat-free or low-fat milk and milk products | 2-3 | 2-3 | 2-3 | 2-3 | 2–3 | 3 | 1 cup milk or yogurt1½ oz cheese | Fat-free milk or buttermilk; fat-free, low-fat, or reduced-fat cheese; fat-free/low-fat regular or frozen yogurt | Major sources of calcium and protein |
| Lean meats, poultry, and fish | 3 or less | 3-4 or less | 3-4 or less | 6 or less | 6 or less  | 6 or less | 1 oz cooked meats, poultry, or fish1 egg‡ | Select only lean; trim away visible fats; broil, roast, or poach; remove skin from poultry | Rich sources of protein and magnesium |
| Nuts, seeds, and legumes | 3 per week | 3 per week | 3-4 per week | 4 per week | 4–5 per week | 1 | 1/3 cup or 1½ oz nuts2 Tbsp peanut butter2 Tbsp or ½ oz seeds½ cup cooked legumes (dried beans, peas) | Almonds, filberts, mixed nuts, peanuts, walnuts, sunflower seeds, peanut butter, kidney beans, lentils, split peas | Rich sources of energy, magnesium, protein, and fiber |
| Fats and oils^ | 1 | 1 | 2 | 2-3 | 2-3 | 3 | 1 tsp soft margarine1 tsp vegetable oil1 Tbsp mayonnaise2 Tbsp salad dressing | Soft margarine, vegetable oil (canola, corn, olive, safflower), low-fat mayonnaise light salad dressing | DASH study had 27% of calories as fat, including fat in or added to foods. |
| Sweets and added sugars | 3 or less per week | 3 or less per week | 3 or less per week | 5 or less per week | 5 or less per week | < 2 | 1 Tbsp sugar1 Tbsp jelly or jam½ cup sorbet, gelatin dessert1 cup lemonade | Fruit-flavored gelatin, fruit punch, hard candy, jelly, maple syrup, sorbet and ices, sugar | Sweets should be low in fat. |

\* Whole grains are recommended for most grain servings as a good source of fiber and nutrients.

† Serving sizes vary between ½ cup and 1 1/4 cups, depending on cereal type. Check product’s Nutrition Facts label.

‡ Two egg whites have the same protein content as 1 oz meat.

^ Fat content changes serving amount for fats and oils. For example, 1 Tbsp regular salad dressing = one serving; 1 Tbsp low-fat dressing = one-half serving; 1 Tbsp fat-free dressing = zero servings.

Abbreviations: oz = ounce; Tbsp = tablespoon; tsp = teaspoon.

Successful weight loss programs in children and adolescents include frequent contact for support and monitoring by the physician and/or dietitian, as often as weekly for the first 6 months and this should be considered when initiating diet changes for children with CD (166). While not necessary for lipid management, a repeat fasting lipid panel after 1 to 3 months of diet change can be an effective motivator for children and families since TG levels decrease rapidly in response to changes in diet composition and even minimal weight loss (167).

A regular exercise schedule derived from the evidence is prescribed, simultaneous with the diet recommendations. All children and adolescents should be involved in 60 minutes or more of moderate to vigorous aerobic activity daily, with vigorous intensity activity at least 3 days/week (1,168,169). Any kind of aerobic activity is useful but weight bearing activity is most effective. To promote compliance, a discussion about the kind of exercise that will be easiest for each child and family to sustain should be undertaken and specific follow-up of activity at subsequent evaluations is recommended. A combined diet and activity approach to weight loss like this has been shown to be effective in management of high TGs and CD (167-174).

For obese children and their families, weight loss can be an emotional issue so an alternative approach aimed at changing diet composition and activity without a direct approach to weight can be used. The same diet change and activity recommendations described above are prescribed but there is no calculation of caloric needs and no specific focus on weight loss. This approach has been shown to be successful in addressing high TGs and CD, particularly when combined with cognitive behavioral therapy (167,174-180).

**Follow-Up**

After 6 months of the selected diet and activity plan, the fasting lipid profile (FLP) should be repeated:

* If TGs are normal (<100 mg/dL, <10 years; <130 mg/dL, 10–19 years), continue the diet and activity recommendations and reassess the FLP every 12 months
* If TGs are > 100 mg/dL but < 200 mg/d in children < 10 years of age, > 130 mg/dL but < 200 mg/dL in 10-19 years old:
* Intensify counselling for the high TG/CD diet and increased activity.
* Recommend increased dietary fish content.
* Increase frequency of contact with MD and/or RD.
* Repeat FLP in 6 months
* If TG are > 200 mg/dL but less than 500 mg/dL and lifestyle recommendations have been attempted with no weight loss, consider referral to an intensive weight loss program (1).
* If TG are > 200 mg/dL but less than 500 mg/dL despite weight loss in an adolescent who has at least 2 additional high-level cardiovascular risk factors (table 5), medication can be considered (1).

|  |
| --- |
| **Table 5. High Level Cardiovascular Risk Factors for Management of Combined Dyslipidemia in Childhood**  |
| (+) Family history: Myocardial infarction, angina, coronary artery bypass graft/ stent/ angioplasty, sudden cardiac death in parent, grandparent, aunt, or uncle; Male < 55 y, female < 65 y. |
| Diabetes mellitus, type 1 or type 2 |
| Hypertension requiring drug treatment |
| Current cigarette smoking |
| BMI>97th%ile |

Application of these recommendations is usually associated with significant improvements in hypertriglyceridemia and CD on intermediate-term follow-up, with increasing evidence of lipid subpopulation and vascular response to lifestyle change. There are no published long-term studies of lifestyle change.

**MEDICATION THERAPY FOR HYPERTRIGLYCERIDEMIA AND COMBINED DYSLIPIDEMIA**

Information on drug therapy for treatment of hypertriglyceridemia and CD in childhood is limited. Drugs which could potentially be used are described below.

**HMG-CoA Reductase Inhibitors (Statins)**

In adults with high cholesterol and CD, statin therapy beneficially alters the standard lipid and LDL particle profiles and improves vascular function and clinical cardiovascular outcomes (181-183). In childhood, statin treatment has focused on children with monogenic hyper-cholesterolemia (FH) in whom statins effectively lower LDL-C levels and improve LDL-C subpopulation characteristics (184,185). Two pediatric trials of children with FH showed improved vascular measures in response to statin therapy (185,186). There are as yet no published studies examining statin effects on clinical outcomes in youth with CD**.** A systematic review of statin therapy in children with FH analyzed studies that included more than 1000 children (188). Treatment with statins significantly decreased LDL-C but change in TGs was much less consistent. No statistically significant differences were found between statin-treated and placebo-treated children for the occurrence of any adverse events, including problems with sexual development, muscle toxicity, or liver toxicity. An important study reported late follow-up of 184 patients with genetically confirmed familial hypercholesterolemia (FH) who were started on pravastatin therapy at a mean age of 12 years as part of a placebo-controlled trial. After 20 years, FH participants had mean LDL cholesterol levels 32% below baseline levels in the original trial. Mean progression of carotid intima–media thickness in FH subjects was similar to that of unaffected siblings. The cumulative incidence of cardiovascular events and death from cardiovascular causes was lower among the FH participants than among their affected parents for whom statins were available much later in life. This landmark report emphasizes the safety, effectiveness and benefit of long-term statin therapy initiated in childhood for treatment of FH (189).  DoIt!, an ongoing Pediatric Heart Network trial is evaluating the clinical and vascular responses to statin therapy in adolescents with obesity and CD. Enrollment is ongoing with a planned sample size of more than 300 subjects. Results are anticipated soon (190).

**Omega-3 Fish Oil**

Omega-3 fish oil therapy has been shown to be safe in adults, with some reports that TG levels decreased by as much as 30–45%, with associated increases in HDL–C (191). However, more recent reports including a Cochrane systematic review of 25 randomized, controlled trials have shown no conclusive benefits of standard fish oil treatment (usually 1 gram per day) on serum lipids or cardiovascular disease outcomes (192-194). Two randomized, controlled trials of omega-3 fish oil in adolescents showed statistically insignificant decreases in TGs and no change in LDL particle number or size (195,196). Evidence from multiple trials in adults with established CV risk shows conflicting results for benefit from omega-3 fatty acids and/or EPA. A detailed discussion of the potential benefits of omega-3-fattys on cardiovascular outcomes are discussed in detail in other Endotext chapters. There is as yet no information on use of EPA in children or adolescents.

**PPAR-Alpha Agonists (Fibrates)**

In adults, fibrates have been used effectively and safely to lower TG levels, alone and in combination with statins (fenofibrate should be used in combination as gemfibrozil increases the risk of muscle disorders) (197). Fibrates reduce cholesterol synthesis and lower plasma TGs by 30-50% with an increase in HDL-C of 2-20%. Fibrate therapy beneficially alters LDL subclass distribution with an increase in LDL size and a decrease in LDL particles (198).

In children, treatment with fibrates in a single small randomized trial (n=14) and 3 case series (n=7, n=17, n=47) was associated with significant TG lowering by as much as 54% with an associated 17% increase in HDL-C (199-202). One child was thought to have myositis on clinical grounds with no lab changes and there were mild, transient elevations in liver enzymes in 2 subjects but no other potentially adverse effects were reported. There are no long-termtrials of fibrates in children and no studies of the vascular or clinical response to treatment.

**Summary**

Evidence for drug therapy of moderate hypertriglyceridemia or CD in childhood is limited. Statins improve LDL-C subpopulation characteristics on NMR analysis in children with FH (184,185). There is substantial evidence that statins as a group are safe and effective for long-term treatment of hypercholesterolemia beginning in childhood (189). Despite concern about hepatic side-effects, current evidence indicates that statins are safe in patients with NAFLD and may improve liver function tests (203). Statin therapy therefore appears to be the logical theoretical choice for treatment of CD if drug therapy is needed. The possibility of eicosapentaenoic acid (EPA) as secondary treatment for adults with established CVD and residual risk due to high TGs represents a theoretical treatment option but results are controversial and there is no reported experience for use in youth (204). There are no current trials of any other medication in children with combined dyslipidemia. A large body of evidence indicates that lifestyle therapy is highly effective for management of CD in youth and that a decision to initiate drug treatment should only be made in an adolescent with multiple additional high-level risk factors after intensive long-term efforts at lifestyle modification.

**CONCLUSION**

In youth, CD is a prevalent, highly atherogenic lipid disorder, almost always associated with obesity. High TGs and CD are strongly associated with a complex of related risk factors including visceral adiposity, insulin resistance/T2DM, NAFLD, and the metabolic syndrome complex which significantly exponentiate risk for CVD. Primary therapy is lifestyle change focused on weight loss, change in diet composition, and increased activity. These interventions are usually very effective. Drug therapy is only rarely needed in the multiple risk adolescent with CD with statin medications as the theoretical drug of choice.

**REFERENCES**

1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: National Heart, Lung and Blood Institute. Pediatrics 2011;128(Suppl 5):S213-256; www.nhlbi.nih.gov/guidelines/cvd\_ped/index.htm.

2. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. *Clin Cardiol*. 1999;22:II21-7.

3. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175-80.

4. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-7.

5. Krauss RM. Dense low density lipoproteins and coronary artery disease. Am J Cardiol 1995;75(6):53B-57B.

6. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1) trial. Am J Cardiol 2002;90(2):89-94.

7. El Harchaoui K, van der Steeg WA, Stroes ES et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population study. J Am Coll Cardiol 2007;49(5):547-553.

8. Mackey RH, Kuller LH, Sutton-Tyrrell K et al. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the Healthy Women study. Am J Cardiol 2002;90(8A):71i-76i.

9. Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113(12):1556-1563.

10. Cromwell WC, Otvos JD, Keyes MJ et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study – Implications for LDL management. J Clin Lipidol 2007;1(6):583-592.

11. Arca M, Montali A, Valiente S et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol 2007;100(10):1511-1516.

12. [Hoff HF](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hoff%20HF%5BAuthor%5D&cauthor=true&cauthor_uid=165805), [Titus JL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Titus%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=165805), [Bajardo RJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bajardo%20RJ%5BAuthor%5D&cauthor=true&cauthor_uid=165805), [Jackson RL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Jackson%20RL%5BAuthor%5D&cauthor=true&cauthor_uid=165805) et al. Lipoproteins in atherosclerotic lesions. Localization by immunofluorescence of apo-low density lipoproteins in human atherosclerotic arteries from normal and hyperlipoproteinemics. [Arch Pathol.](http://www.ncbi.nlm.nih.gov/pubmed/165805) 1975 May;99(5):253-8.

13. Nigon F, Lesnik P, Rouis M et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32:1741-1753.

14. [Berneis K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Berneis%20K%5BAuthor%5D&cauthor=true&cauthor_uid=15045696), [Shames DM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shames%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=15045696), Blanche PJ et al. Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter.[Metabolism.](http://www.ncbi.nlm.nih.gov/pubmed?term=(berneis%20k)%20AND%20shames%20dm) 2004 Apr;53(4):483-7.

15. [La Belle M](http://www.ncbi.nlm.nih.gov/pubmed/?term=La%20Belle%20M%5BAuthor%5D&cauthor=true&cauthor_uid=2246611), [Krauss RM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Krauss%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=2246611). Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res 1990 Sep;31(9):1577-88.

16. Olin-Lewis K, Krauss RM, La Belle M et al. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002;43(11):1969-1977.

17. [Shin MJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shin%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=20303494), [Krauss RM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Krauss%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=20303494). Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men. [Atherosclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/20303494) 2010; 211(1):337-41.

18. De Graaf J, Hak-Lemmers HL, Hectors MP et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298-306.

19. Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS Data Brief. 2017 Oct;(288):1-8.

20. Deshmukh-Taskar P, Nicklas TA, Morales M, Yang SJ, Zakeri I and Berenson GS. Tracking of overweight status from childhood to young adulthood: the Bogalusa Heart Study. *Eur J Clin Nutr*. 2006;60:48-57.

21. Freedman DS, Mei Z, Srinivasan SR, Berenson GS and Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. *J Pediatr*. 2007;150:12-17 e2.

22. Freedman DS, Dietz WH, Srinivasan SR and Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. *Pediatrics*. 1999;103:1175-82.25.

23. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH and Looker HC. Childhood obesity, other cardiovascular risk factors, and premature death. *N Engl J Med*. 2010;362:485-93.

24. Centers for Disease Control and Prevention. Prevalence of abnormal lipid levels among youths --- United States, 1999-2006. MMWR Morb Mortal Wkly Rep;59:29-33.

25. Perak AM, Ning H, Kit BK et al. Trends in lipid levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999-2016. JAMA 2019; 321(19): 1895-1905.

26. Dhuper S, Sakowitz S, Daniels J et al. Association of lipid abnormalities with measures and severity of adiposity and insulin resistance among overweight children and adolescents. J Clin Hypertes (Greenwich) 2009; 11:594-600.

27. Korsten-Reck U, Kromeyer-Hauschild K, Korsten K et al. Frequency of secondary dyslipidemia in obese children. Vasc Health Risk Manag 2008; 4: 1089-1094.

28. Bell LM, Curran JA, Byrne S et al. High incidence of obesity co-morbidities in young children: a cross-sectional study. J Paediatr Child Health 2011;47: 911-917.

29. Salvatore D, Satnick A, Abell R et al. The prevalence of abnormal metabolic parameters in obese and overweight children. JPEN J Parenter Enteral Nutr 2014; 38: 852-855.

30. Friedemann C, Heneghan C, Mahtani K et al. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ 2012; 345: e4759.

31. Margolis KL, Greenspan LC, Trower NK et al. Lipid screening in children and adolescents in community practice: 2007-2010. Circ Cardiovasc Qual Outcomes 2014; 7:718-726.

32. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302(16):1765-1773.

33. Findling RL, McNamara NK, Gracious BL. Pediatric uses of atypical antipsychotics. Expert Opin Pharmacother 2000; 1(5):935-945.

34. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 2006;118(1):201-206.

35. Rainwater DL, McMahan CA, Malcom GT, Scheer WD, Roheim PS, McGill HC Jr, Strong JP. Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler Thromb Vasc Biol 1999;19(3):753-761.

36. Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol 2007;100(1):64-8.

37. [Rana JS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rana%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=22203405)1, [Boekholdt SM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Boekholdt%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=22203405), [Kastelein JJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kastelein%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=22203405), [Shah PK](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shah%20PK%5BAuthor%5D&cauthor=true&cauthor_uid=22203405). The role of non-HDL cholesterol in risk stratification for coronary artery disease. [Curr Atheroscler Rep.](http://www.ncbi.nlm.nih.gov/pubmed/22203405) 2012 Apr;14(2):130-4. doi: 10.1007/s11883-011-0224-x.

38. [Boekholdt SM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Boekholdt%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=22453571)1, [Arsenault BJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arsenault%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=22453571), [Mora S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mora%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22453571) et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. See comment in PubMed Commons below[JAMA.](http://www.ncbi.nlm.nih.gov/pubmed/22453571) 2012 Mar 28;307(12):1302-9.

39. Gaziano JM, Michael J, Hennekens CH et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96**:** 2520-2525.

40. da Luz PL, Favorato D, Faria-Neto JR et al. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics(Sao Paulo) 2008;63(4):427-432.

41. Hannon TS, Bacha F, Lee SJ et al. Use of markers of dyslipidemia to identify overweight youth with insulin resistance. Pediatr Diabetes 2006;7:260-266.

42. DiBonito P, Moio N, Scilla C et al. Usefulness of the high triglyceride-to-HDL cholesterol ratio to identify cardiometabolic risk factors and preclinical signs of organ damage in outpatient children. Diabetes Care 2012;35(1):158-162.

43. Pacifico L, Bonci E, Andreoli G et al. Association of serum triglyceride-to–HDL cholesterol ratio with carotid intima media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis 2014;24(7):737-743.

44. Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care 2011;34:1869e74.

45. Hoffman R. Increased fasting triglyceride levels are associated with hepatic insulin resistance in Caucasian but not African-American adolescents. Diabetes Care 2006;29(6): 1402-1404.

46. Sumner AE. Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. J Pediatr 2009;155(3):S7.4-S7.11.

47. D’Adamo E, Northrup V, Weiss R et al . Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr 2010;92:500-508.44.

48. Burns SF, Lee SJ, Arslanian SA. [Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth.](http://www.pubfacts.com/detail/22809659/Surrogate-lipid-markers-for-small-dense-low-density-lipoprotein-particles-in-overweight-youth.) J Pediatr 2012 Dec 17;161(6):991-6. Epub 2012 Jul 17.

49. Marcus MD, Baranowski T, DeBar LL, Edelstein S, Kaufman FR, Schneider M, Siega-Riz AM, Staten MA, Virus A and Yin Z. Severe obesity and selected risk factors in a sixth grade multiracial cohort: the HEALTHY study. J Adolesc Health. 2010;47:604-7

50. Mietus-Snyder M, Drews KL, Otvos JD, Willi SM, Foster GD, Jago R and Buse JB. Low-density lipoprotein cholesterol versus particle number in middle school children. JPediatr. 2013;163:355-62.

51. Miller M. Managing mixed dyslipidemia in special populations.[Prev Cardiol.](http://www.ncbi.nlm.nih.gov/pubmed/20377810)2010;13(2): 78-83.

52. [Wu L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20L%5BAuthor%5D&cauthor=true&cauthor_uid=25242435), [Parhofer KG](http://www.ncbi.nlm.nih.gov/pubmed/?term=Parhofer%20KG%5BAuthor%5D&cauthor=true&cauthor_uid=25242435). Diabetic dyslipidemia.[Metabolism.](http://www.ncbi.nlm.nih.gov/pubmed/25242435) 2014 Dec;63(12):1469-79. Epub 2014 Aug 29.

53. Kavey RE. Combined dyslipidemia in childhood. J Clin Lipidol. 2015 Sep-Oct;9(5 Suppl):S41-56. doi: 10.1016/j.jacl.2015.06.008. Epub 2015 Jun 17.

54. Goldstein JL, Schrott HG, Hazzard WR et al. Hyperlipidemia in coronary artery disease. II. Genetic analysis of of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-1568.

55. Gaddi A, Cicero AF, Odoo FO, Poli AA and Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vascular health and risk management. 2007;3:877-86.

56. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev 2015;36(1): 131-147.

57. Brouwers MCGJ, van Greevenbroek MMJ, Stehouwer CDA et al. The genetics of familial combined hyperlipidemia. Nat Rev Endocrinol 2012;8:352-362.

58. Lee KE, Klein BE, Klein R. Familial aggregation of components of the multiple metabolic syndrome in the Framingham Heart and Offspring Cohorts. BMC Genet 2003;4(Suppl 1):S94.

59. Montali A, Truglio G, Martino F et al. Atherogenic dyslipidemia in children: Evaluation of clinical, biochemical and genetic aspects. PLoS ONE 2015; 10(4):doi:10.1371/jour.pone.0120099.nal

60. Crosby J, Peloso GM, Auer PL et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371(1):22-31.

61. Pauciullo P, Gentile M, Marotta G, Baiano A, Ubaldi S, Jossa F, Iannuzzo G, Faccenda F, Panico S and Rubba P. Small dense low-density lipoprotein in familial combined hyperlipidemia: Independent of metabolic syndrome and related to history of cardiovascular events. Atherosclerosis. 2009;203:320-4.

62. Ayyobi AF et al. Small, dense LDL and elevated apoliporotein B are common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003;23:1289-1294.

63. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-44.

64. McGill HC, Jr., McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC and Strong JP. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20:1998-2004.

65. Newman WP, 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986;314:138-44.

66. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE and Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-6.

67. Wunsch R, de Sousa G and Reinehr T. Intima-media thickness in obesity: relation to hypertension and dyslipidaemia. Arch Dis Child. 2005;90:1097.

68. Fang J, Zhang JP, Luo CX, Yu XM and Lv LQ. Carotid intima-media thickness in childhood and adolescent obesity: relationship to abdominal obesity, high triglyceride level and insulin resistance. Int J Med Sci. 2010;7:278-83.

69. Ayer JG, Harmer JA, Nakhla S, Xuan W, Ng MK, Raitakari OT, Marks GB and Celermajer DS. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Arterioscler Thromb Vasc Biol. 2009;29:943-9.

70. Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels SR and Kimball TR. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics. 2013;131:e1082-90.

71. Juonala M, Viikari JS, Ronnemaa T, Marniemi J, Jula A, Loo BM and Raitakari OT. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young FinFinns Study. Arterioscler Thromb Vasc Biol. 2008; 28:1012-7.

72. Magnussen CG, Venn A, Thomson R, Juonala M, Srinivasan SR, Viikari JS, Berenson GS, Dwyer T and Raitakari OT. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood: evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol. 2009;53:860-9.

73. Koivistoinen T, Hutri-Kahonen N, Juonala M, Koobi T, Aatola H, Lehtimaki T, Viikari JS, Raitakari OT and Kahonen M. Apolipoprotein B is related to arterial pulse wave velocity in young adults: the Cardiovascular Risk in Young Finns Study. *Atherosclerosis*. 2011;214:220-4.

74. [Morrison JA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Morrison%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19501856), [Glueck CJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Glueck%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=19501856), [Horn PS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Horn%20PS%5BAuthor%5D&cauthor=true&cauthor_uid=19501856), [Yeramaneni S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yeramaneni%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19501856), [Wang P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20P%5BAuthor%5D&cauthor=true&cauthor_uid=19501856). Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life**.**See comment in PubMed Commons belowMetabolism 2009; 58(9):1277-1284. Epub 2009 Jun 18.

75. Morrison JA, Glueck CJ and Wang P. Childhood risk factors predict cardiovascular disease, impaired fasting glucose plus type 2 diabetes mellitus, and high blood pressure 26 years later at a mean age of 38 years: the Princeton-lipid research clinics follow-up study. Metabolism. 2012;61:531-41.

76. Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected cardiovascular risk factor. Cardiovasc Diabetol 2014; 13:159-161.

77. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk M 2016;12:171-183.

78. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics and biology. Circ Res 2016; 118(4):547-563.

79. [Nichols GA, Phillip S, Reynolds K. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL-cholesterol. *J. Clin. Endocrinol. Metab.* 2018. 103:3019-3027](http://www.ncbi.nlm.nih.gov/pubmed/29850861)

80. [Ganda OP et al. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. *J. Am. Coll. Cardiol.* 2018. 72:330-34](http://www.ncbi.nlm.nih.gov/pubmed/29935936).

81. Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 2001;357:505-508.

82. Malik VS, Matthias B Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr 2006;84:274–88.

83. Van Rompay MI, McKeown NM, Goodman E et al. Sugar-sweetened beverage intake is positively associated with baseline triglyceride concentrations and changes in intake are inversely associated with changes in HDL cholesterol over 12 months in a multi-ethnic sample of children. J Nutr 2015; 145(10):2389-2395.

84. Kell KP, Cardel MI, BohanBrown MM et al. Added sugars in the diet are positively associated with diastolic BP and triglycerides in children. Am J Clin Nutr 2014; 100(1): 46-52.

85. Zhang Z, Gillespie C, Welsh JA et al. Usual intake of added sugars and lipid profiles among U.S. adolescents: National Health and Nutrition Examination Survey, 2005-2010. J Adolesc Health 2015; 56(3):352-359.

86. Sonneville KR, Long MW, Rifas-Shimon SL et al. Juice and water intake in infancy and later beverage intake and adiposity: could juice be a gateway drink? Obesity 2015; 23(1):170-176.

87. Lin W-T, Chan T-F, Huang H-L et al. Fructose-rich beverage intake and central adiposity, uric acid and pediatric insulin reference. J Pediatr 2016;171:90-96.

88. Lee AK, Binongo JN, Chowdhury R et al. Consumption of less than 10% of total energy from added sugars is associated with increasing HDL in females during adolescence: a longitudinal analysis. J Am Heart Assoc 2014;3(1):e0006 15.

89. Jensen MD. Role of body fat distribution and the metabolic consequences of obesity. J Clin Endocrinol Metab 2008;93:S57-S63.

90. de Lemos JA, Neeland IJ. Separating the VAT from the FAT. New insights into the cardiometabolic risks of obesity. J Am Coll Cardiol Img 2014;7(12):1236-1238.

91. Taylor RW, Jones IE, Williams SM et al. Evaluation of waist circumference, waist-to-hip ratio and the conicity index as screening tools for high trunk fat mass, as measured by dual-energy X-ray absorptiometry in children aged 3-19 y. Am J Clin Nutr 2000;72;490-495.

92. Bassali R, Waller JL, Gower B et al. Utility of waist circumference percentile for risk evaluation in obese children. J Pediatr Obes 2011;5: 97-101.

93. Fryar CD, Gu Q, Ogden CL. Anthropometric reference data for children and adults: United States, 2007–2010. National Center for Health Statistics. Vital Health Stat 11(252). 2012.

94. Li C, Ford ES, Mokdad AH, Cook S. Recent trends in waist circumference and waist-height ratio among US children and adolescents. Pediatrics 2006;118: e1390-1398.

95. Khoury M, Manlhiot C, McCrindle BW. Role of the waist/height ratio in the cardiometabolic risk assessment of children classified by body mass index. J Am Coll Cardiol 2013;62: 742-751.

96. Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related consequences. J Clin Endocrin Metab 2004;89(6):2590-2594.

97. Chan JCN, Malik V, Jia W et al. Diabetes in Asia: epidemiology, risk factors and pathophysiology. JAMA 2009;301(20):2129-2140.

98. Shah RV, Murthy VL, Abbasi SA et al. Visceral adiposity and the risk of the metabolic syndrome across body mass index: the MESA study. J Am Coll Cardiol Imag 2014;7(12):1236-1238.

99. Robins SJ, Lyass A, Zachariah JP, Massaro JM and Vasan RS. Insulin resistance and the relationship of dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2011;31:1208-14.

100. Arslanian S, Suprasongsin C. Insulin sensitivity, lipids and body composition in childhood: is syndrome X present? J Clin Endocrinol Metab 1996;81:1058-1062.

101. Srinivasan SR, Frontini MG, Berenson GS. Longitudinal changes in risk variables of insulin resistance syndrome from childhood to young adulthood in offspring of parents with type 2 diabetes: the Bogalusa Heart Study. Metabolism 2003;52(4):443-450.

102. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes and cardiovascular risk in children. A scientific statement from the American Heart Association. Circulation 2003;107: 1448-1453.

103. Zavaroni I, Alpi O et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis 1985; 55:259-266.

104. Lapur CN, Yost TJ, Eckel RH. Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 1984;59:1176-1182.

105. Steinberger J, Moorehead C, Katch V et al. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr 1995;126(5 pt 1):690-695.

106. Dabalea D, Mayer-Davis EJ, Saydah S et al. SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014;311(17): 1778-1786.

107. Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: A brief review. Curr Diab Rep 2019; 127. Doi:10.1007/s11892-018-1101-6.

108. Vajro P, Lenta S, Socha P et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012;54(5):700-713.

109. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non-alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatrics 2013;13:40-50.

110. Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health problem. Eur J Pediatr 2014; 173: 131-139.

111. Molleston JP, Schwimmer JB, Yates KP et al. Histological abnormalities in children with non-alcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014;164(4):707-713.

112. [Mann JP](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mann%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=25633064), [Goonetilleke R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Goonetilleke%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25633064), [McKiernan P](http://www.ncbi.nlm.nih.gov/pubmed/?term=McKiernan%20P%5BAuthor%5D&cauthor=true&cauthor_uid=25633064). Paediatric non-alcoholic fatty liver disease: a practical overview for non-specialists. [Arch Dis Child.](http://www.ncbi.nlm.nih.gov/pubmed/25633064) 2015 Jan 29. [Epub ahead of print]**.**

113. Fusillo S, Rudolph B. Nonalcoholic fatty liver disease.[Pediatrics in Review](http://pedsinreview.aappublications.org/) 2015; 36(5): 198-206.

114. Nobili V, Marcellini M, Devito R et al. NAFLD in children: a prospective clinical pathological study and effect of lifestyle advice. Hepatology 2006;44:458-465.

115. Alkhouri N, Carter-Kent C, Elias M, Feldstein AE. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol 2011;6(3):305-314.

116. Schwimmer JB, Ugalde-Nicalo P, Welsh JA et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys. JAMA 2019;321(3):256-265.

117. Pacifico L, Chiesa C, Anania C et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gatroenterol 2014;20(27):9055-9071.

118. [Than NN](http://www.ncbi.nlm.nih.gov/pubmed/?term=Than%20NN%5BAuthor%5D&cauthor=true&cauthor_uid=25617860), [Newsome PN](http://www.ncbi.nlm.nih.gov/pubmed/?term=Newsome%20PN%5BAuthor%5D&cauthor=true&cauthor_uid=25617860). A concise review of non-alcoholic fatty liver disease. [Atherosclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/25617860) 2015 Mar;239(1):192-202. Epub 2015 Jan 13.

119. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.

120. Marchesisn G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50(8):1844-1850.

121. Beltran-Sanchez H, Harhay MO, Harhay MM et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 199-210. J Am Coll Cardiol 2013;62:697-703.

122. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-359.

123. Steinberger J, Daniels SR, Eckel RH et al. Progress and challenges in metabolic syndrome in children and adolescents: A scientific statement from the American heart Association. Circulation 2009; 119:628-647.

124. De Ferranti SD, Gauvreau K, Ludwig DS et al. Prevalence of the metabolic syndrome in American adolescents: findings from the third national health and nutrition survey. Circulation 2004; 110:2494-2497.

125. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007; 120:340-345.

126. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes and cardiovascular risk in children. A scientific statement from the American Heart Association. Circulation 2003;107: 1448-1453.

127. Gidding SS, Stone NJ, Bookstein LC et al. Month-to-month variability of lipids, lipoproteins and apolipoproteins and the impact of acute infection in adolescents. J Pediatr 1998;133(2):242-246.

128. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease. A scientific statement from the American Heart Association. Circulation 2011;123::2292-2333.

129. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care 2000;23(3):381-389. Used prev?

130. Epstein LH, Kuller LH, Wing RR, Valoski A, McCurley J. The effect of weight control on lipid changes in obese children. Am J Dis Child 1989;143(4):454-457.

131.Nemet D, Barkan S, Epstein Y, Friedland O, Kowen G, Eliakim A. Short- and long-term beneficial effects of a combined dietary-behavioral-physical activity intervention for the treatment of childhood obesity. Pediatrics 2005;115(4):e443-e449.

132. Becque MD, Katch VL, Rocchini AP, Marks CR, Moorehead C. Coronary risk incidence of obese adolescents: reduction by exercise plus diet intervention. Pediatrics 1988; 81(5):605-612.

133. Reinehr T, Andler W. Changes in the atherogenic risk factor profile according to degree of weight loss. Arch Dis Child 2004; 89:419-422.

134. Kirk S, Zeller M, Claytor R et al. The relationship of health outcomes to improvement of BMI in children and adolescents. Obes Res 2005;13:876-882.

135. Ho M, Garnett SP, Baur LA et al. Impact of dietary and exercise interventions on weight change and metabolic outcomes in obese children and adolescents: a systematic review and meta-analysis of randomized trials. JAMA Pediatr 2013; 167:759-768.

136. Roberts CK. Combined diet and exercise interventions can improve metabolic outcomes in obese children, even with only small changes in weight. Evid Based Med 2014;19:e9.

137. Hobkirk JP, King RF, Davies I et al. The metabolic inter-relationships between changes in waist circumference, triglycerides, insulin sensitivity and small, dense low-density lipoprotein particles with acute weight loss in clinically obese children and adolescents. Pediatr Obes 2014;9(3): 209-217.

138. Pieke B, von Eckardstein A, Gulbahce E, Chirazi A, Schulte H, Assmann G, Wahrburg U. Treatment of hypertriglyceridemia by two diets rich in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin. Int J of Obesity 2000;24:1286-1296.

139. Ohta T, Nakamura R, Ikeda Y, Hattori S, Matsuda I. Follow up study on children with dyslipidaemia detected by mass screening at 18 months of age: effect of 12 months dietary treatment. Eur J Pediatr 1993;152(11):939-943.

140. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA. 2004 Nov 24;292(20):2482-90.

141. Ebbeling CB, Leidig MM, Sinclair KB, Seger-Shippee LG, Feldman HA, Ludwig DS. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr. 2005 May;81(5):976-82.

142. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low glycemic-load vs low fat diet in obese young adults. JAMA 2007;297:2092-2102.

143. Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS. A reduced glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003;157:773-779.

144. De Ferranti SR, Milliren CE, Denhoff ER et al. Providing food to treat adolescents at risk for cardiovascular disease. Obesity 2015; 23: 2109-2117.

145. Sondike SB, Copperman N, Jacobson MS. Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factors in overweight adolescents. J Pediatr 2003;142(3):253-258. 98.Kirk S, Brehm B,

146. Saelens BE, Woo JG, Kissel E, D'Alessio D, Bolling C and Daniels SR. Role of Carbohydrate Modification in Weight Management among Obese Children: A Randomized Clinical Trial. *J Pediatr*. 2012;161:320-327.

147. Wooten JS, Biggerstaff KD and Ben-Ezra V. Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise. J ApplPhysiol. 2009;107:794-800.

148. Siri-Tarino PW, Williams PT, Fernstrom HS, Rawlings RS and Krauss RM. Reversal of small, dense LDL subclass phenotype by normalization of adiposity. Obesity (Silver Spring). 2009;17:1768-75.

149. Anderssen SA, Cooper AR, Riddoch C et al. Low cardiorespiratory fitness is a strong predictor for clustering of cardiovascular risk factors in children independent of country, age and sex. Eur J Cardiovasc Prev Rehabil 2007;14:5526-531.

150. Lobelo F, Pate RR, Dowda M et al. Cardiorespiratory fitness and clustered cardiovascular disease risk in US adolescents. J Adolesc Health 2010;47:352-359.

151. Ruiz JR, Ortega FB, Rizzo NS et al. High cardiovascular fitness is associated with a low metabolic risk score in children: the European Youth Heart Study. Pediatr Res 2007:61:350-355.

152. Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in children and adolescents: a meta-analysis of randomized controlled trials. Atherosclerosis 2007;191:447-453.

153.Ferguson MA, Gutin B, Le NA, Karp W, Litaker M, Humphries M, Okuyama T, Riggs S, Owens S. Effects of exercise training and its cessation on components of the insulin resistance syndrome in obese children. Int J Obes Relat Metab Disord 1999;23(8):889-895.

154. Kang HS, Gutin B, Barbeau P, Owens S, Lemmon CR, Allison J, Litaker MS, Le NA. Physical training improves insulin resistance syndrome markers in obese adolescents. Med Sci Sports Exerc 2002;34(12):1920-1927.

155. Escalente Y, Saavedra JM, Garcia-Hermoso A et al. Improvement of the lipid profile with exercise in obese children: a systematic review. Prev Med 2012; 54:293-301.

156. Janssen I, LeBlanc AG. Systematic review of the health benefits of physical activity and fitness in school-aged children and youth. Int J Beh Nutr Phys Activity 2010; 7: 40-56.

157. Guidelines for Physical Activity in Americans. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Division of Nutrition, Physical Activity, and Obesity. Office of Disease Prevention and Health Promotion. 2008. <http://www.health.gov/PAGuidelines/>

158. Davis CL, Pollock NK, Waller JL et al. Exercise dose and diabetes risk in overweight and obese children. A randomized controlled trial. JAMA 2012;308(11):1103-1112.

159. [Hansen BH](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hansen%20BH%5BAuthor%5D&cauthor=true&cauthor_uid=29626333), [Anderssen SA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Anderssen%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=29626333), [Andersen LB](https://www.ncbi.nlm.nih.gov/pubmed/?term=Andersen%20LB%5BAuthor%5D&cauthor=true&cauthor_uid=29626333)et al. Cross-sectional associations of reallocating time between sedentary and active behaviors on cardiometabolic risk factors in young people: an International Children's Accelerometry Database (ICAD) analysis. [Sports Med.](https://www.ncbi.nlm.nih.gov/pubmed/29626333) 2018 Oct;48(10):2401-2412. doi: 10.1007/s40279-018-0909-1.

160. Laitinen TT, Pahkala K, Magnussen CG, Viikari JS, Oikonen M, Taittonen L, Mikkila V, Jokinen E, Hutri-Kahonen N, Laitinen T, Kahonen M, Lehtimaki T, Raitakari OT and Juonala M. Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2012;125:1971-8.

161. Nordstrand N, Gjevestad E, Hertel JK, Johnson LK, Saltvedt E, Roislien J and Hjelmesaeth J. Arterial stiffness, lifestyle intervention and a low-calorie diet in morbidly obese patients-a nonrandomized clinical trial. *Obesity (Silver Spring)*. 2013;21:690-7.

162. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, Davy BM and Davy KP. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. *Hypertension*. 2010;55:855-61.

163. Kelly AS, Wetzsteon RJ, Kaiser DR, Steinberger J, Bank AJ, Dengel DR. Inflammation, insulin, and endothelial function in overweight children and adolescents: the role of exercise. J Pediatr 2004;145:731-736.

164. Wunsch R, de Sousa G, Toschke AM and Reinehr T. Intima-media thickness in obese children before and after weight loss. *Pediatrics*. 2006;118:2334-40.

165. Meyer AA, Kundt G, Lenschow U et al. Improvement of early vascular changes and cardiovascular risk factors in obese children after a six-month exercise program. J Am Coll Cardiol 2006;48:1865-1870.

166. Whitlock EP, O’Connor EA, Williams SB et al. Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF. Pediatrics 2010;125: e396-e418.

167. Pratt RE, Kavey RE and Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol 2014; 8(2): 181-186.

168. Ekelund U, Luan J, Sherar LB, Esliger DW, Griew P and Cooper A. Moderate to vigorous physical activity and sedentary time and cardiometabolic risk factors in children and adolescents. *JAMA*. 2012;307:704-12.

169. Mello MT, de Piano A, Carnier J et al. Long-term effects of aerobic plus resistance training on the metabolic syndrome and adiponectinemia in obese adolescents. J Clin Hypertens 2011; 13:343-350.

170. Monzavi R, Dreimane D, Geffner ME et al. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics 2006;117(6):1111–1118

171. Szamosi A, Czinner A, Szamosi T et al. Effect of diet and physical exercise treatment on insulin resistance syndrome of schoolchildren. J Am Coll Nutr 2008; 27(1):177–183

172. Caranti DA, de Mello MT, Prado WL et al. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents. Metabolism 2007; 56(9):1293–1300

173. Chen AK, Roberts CK, Barnard RJ. Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children. Metabolism 2006; 55(7):871–878

174. Kasprzak Z, Pilaczyńska-Szcześniak L (2010) Effect of diet and physical activity on physiological and biochemical parameters of obese adolescents. Acta Sci Pol Technol Aliment 2010; 9(1):95–104

175. Katzmarzyk PT, Leon AS, Wilmore JH et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE family study. Med Sci Sports Exer 2003; 35(10):1703–1709

176. Monzavi R, Dreimane D, Geffner ME et al. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics 2006;117(6):1111–1118

177. Pedrosa C, Oliveira BM, Albuquerque I et al. Metabolic syndrome, adipokines and ghrelin in overweight and obese schoolchildren: results of a 1-year lifestyle intervention programme. Eur J Pediatr 2011;170(4):483–492

178. Caranti DA, de Mello MT, Prado WL et al. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents. Metabolism 2007; 56 (9):1293–1300.

179. Tsiros MD, Sinn N, Brennan L. Cognitive behavioral therapy improves diet and body composition in overweight and obese adolescents. Am J Clin Nutr 2008; 87:1134–1140.

180. Bianchini JA, da Silva DF, Nardo CC et al. Multidisciplinary therapy reduces risk factors for metabolic syndrome in obese adolescents. Eur J Pediatr 2013;172(2):215-221.

181. Pontrelli L, Parris W, Adeli K and Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. *Metabolism*. 2002;51:334-42.

182. Hongo M, Kumazaki S, Izawa A, Hidaka H, Tomita T, Yazaki Y, Kinoshita O and Ikeda U. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. *Circ J*. 2011;75:2660-7.

183. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet, January 2015. Published online 1/8/2015.

184. van der Graaf A, Rodenburg J, Vissers MN, Hutten BA, Wiegman A, Trip MD, Stroes ES, Wijburg FA, Otvos JD and Kastelein JJ. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia. *J Pediatr*. 2008;152:873-8.

185. Nozue T, Michishita I, Ito Y and Hirano T. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. *J Atheroscler Thromb*. 2008;15:146-53.

186. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD and Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2002;40:2117-21.

187. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ and Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *JAMA*. 2004;292:331-7.

188. Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2014; 23;7: CD006401.

189. Luirink IK, Wiegman A, Kusters DM et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med 2019; 381:1547-1556. DOI: 10.1056/NEJMoa1816454

[190. Current Studies - Studies - Pediatric Heart Network. www.pediatricheartnetwork.org › Studies › CurrentStudies](http://190.  Current Studies - Studies - Pediatric Heart Network. www.pediatricheartnetwork.org › Studies › CurrentStudies)

191. Goldberg RB, Sabharal AK. Fish oil in the treatment of dyslipidemia. Current Opin Endocrinol Diabetes and Obes 2008;15:167-174.

192. DeCaterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011; 364:2439-2450.

193. Risk Prevention Study Collaborative Group. Roncaglioni MC, Tombesi M, Avanzini F et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013; 368:1800-1808.

194. Abdelhamid AS, Brown TJ, Brainard JS et al. Omega 3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2018, Issue 7. Art. No.: CD003177. DOI: [10.1002/14651858.CD003177.pub3](http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD003177.pub3/full).

195. Gidding SS, Prospero C, Hossain J et al. A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. J Pediatr 2014;165:497-503.

196. de Ferranti SD, Milliren CE, Denhoff ER et al. Using high dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. Clin Pediatr(Phila) 2014;53(5):428-438.

197. Abourbih S, Filion KB, Joseph L et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review. Amer J Med 2009;122:962-980.

198. Guerin M, Bruckert E, Dolphin PJ et al. Fenofibrate reduces plasma cholesterol ester transfer from HDL to VLDL and normalizes the atherogenic dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16:763-772.

199. Wheeler KAH, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985;60(1):34-37.

200. Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clinica Chemica Acta. 1981;112:43–53.

201. Becker M, Staab D, Von Bergmann K. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics. 1992;89:138–42.

202. Smalley CM, Goldberg SJ. A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol 2008;2:106–11.

203. Pastori D, Polimeni L, Baratta F et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease 2015; 47: 4-11.

204. Bhatt D, Steg G, Miller M et al. Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia. NEJM 2019; 380(1): 11-22.